JAK2 and osteosarcoma: Several studies have shown that deguelin effectively inhibited the migration and invasion of triple negative breast cancer and human osteosarcoma cells by downregulating MMP-2 and Janus kinase 2 (JAK2)/STAT3 signaling pathways (Cho et al., 2019; Shang et al., 2014).